Page 175 - ADULT-ONSET ASTHMA PREDICTORS OF CLINICAL COURSE AND SEVERITY
P. 175
REFERENCES
1. GLOBAL BURDEN OF DISEASE DUE TO ASTHMA. Available from h p://globalasthmareport.org/burden/ burden.php; 2014.
2. Global Strategy for Asthma Management and Preven on 2014 (update). 2014.] Available from h p:// www.ginasthma.org/local/uploads/ les/GINA_Pocket_2014_Jun11.pdf.
3. de Marco R, Pa aro C, Locatelli F, Svanes C, Group ES. In uence of early life exposures on incidence and remission of asthma throughout life. J Allergy Clin Immunol 2004; 113:845-52.
4. Kusel MM, de Klerk NH, Kebadze T, Vohma V, Holt PG, Johnston SL, et al. Early-life respiratory viral infec ons, atopic sensi za on, and risk of subsequent development of persistent asthma. J Allergy Clin Immunol 2007; 119:1105-10.
5. Burgess JA, Matheson MC, Gurrin LC, Byrnes GB, Adams KS, Wharton CL, et al. Factors in uencing asthma remission: a longitudinal study from childhood to middle age. Thorax 2011; 66:508-13.
6. Rackemann FM. Intrinsic asthma. Bulle n of the New York Academy of medicine 1947; 23:302-6.
7. Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE. Dis nguishing severe asthma phenotypes: Role of age at onset and eosinophilic in amma on. Journal of Allergy and Clinical Immunology 2004; 113:101-8.
8. Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, et al. Cluster analysis and clinical asthma phenotypes. American Journal of Respiratory and Cri cal Care Medicine 2008; 178:218-24.
9. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li HS, Li XN, et al. Iden ca on of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program. American Journal of Respiratory and Cri cal Care Medicine 2010; 181:315-23.
10. de Nijs SB, Venekamp LN, Bel EH. Adult-onset asthma: is it really di erent? European Respiratory Review 2013; 22:44-52.
11. Wenzel SE. Asthma phenotypes: the evolu on from clinical to molecular approaches. Nature Medicine 2012; 18:716-25.
12. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerba ons and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715-21.
13. Korevaar DA, Westerhof GA, Wang J, Cohen JF, Spijker R, Sterk PJ, et al. Diagnos c accuracy of minimally invasive markers for detec on of airway eosinophilia in asthma: a systema c review and meta-analysis. Lancet Respir Med 2015; 3:290-300.
14. McGrath KW, Icitovic N, Boushey HA, Lazarus SC, Sutherland ER, Chinchilli VM, et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. American Journal of Respiratory and Cri cal Care Medicine 2012; 185:612-9.
15. Has e AT, Moore WC, Li HS, Rector BM, Ortega VE, Pascual RM, et al. Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthma c subjects. Journal of Allergy and Clinical Immunology 2013; 132:72-U150.
16. Westerhof GA, Korevaar DA, Amelink M, de Nijs SB, de Groot JC, Wang J, et al. Biomarkers to iden fy sputum eosinophilia in di erent adult asthma phenotypes. Eur Respir J 2015; 46:688-96.
17. Petsky HL, Cates CJ, Lasserson TJ, Li AM, Turner C, Kynaston JA, et al. A systema c review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012; 67:199-208.
18. Katz LE, Gleich GJ, Hartley BF, Yancey SW, Ortega HG. Blood eosinophil count is a useful biomarker to iden fy pa ents with severe eosinophilic asthma. Ann Am Thorac Soc 2014; 11:531-6.
19. Arron JR, Choy DF, Scheerens H, Ma hews JG. Noninvasive biomarkers that predict treatment bene t from biologic therapies in asthma. Annals of the American Thoracic Society Ann Am Thorac Soc, 2013.
SUMMARY AND GENERAL DISCUSSION
173
